Business Advisory Board

has over 20 years’ experience in the biotech sector, in particular in the field of monoclonal antibodies for the treatment of chronic disease. Nigel has held a series of industry leadership roles including Senior Vice President of Cambridge Antibody Technology, and most recently, CEO and Founder of SweetSpot Therapeutics Ltd. Nigel was entrepreneur-in-residence for Imperial Innovations and has served on multiple national and international scientific and industry advisory boards and committees.

is currently an entrepreneur-in-residence at Polaris Partners. Previously at Genzyme, Mr. Higgins held a variety of leadership roles, including Vice President of Corporate Finance and Vice President of Business Development, and was involved with multiple business units, including Cell Therapy, Gene Therapy and Orphan Diseases.

currently serves as Chairman of Emisphere Technologies Inc. (OTC:EMIS), and Chairman of Speracura LLC, a healthcare consulting company. Mr. Rothwell is the former U.S Chairman for Sanofi-Aventis (Sanofi) after serving as its president and CEO for several years. Earlier in his career, Mr. Rothwell served as CEO of Sandoz Pharmaceuticals and president of Rhone-Poulenc Rorer Pharmaceuticals. Tim has held board positions with several pharmaceutical companies and served as a trustee at the Children’s Health Fund, on the Institute of Medicine’s Evidence-Based Medicine roundtable and as Chairman of the Pheo Para Alliance, a non-profit organization serving patients with pheochromocytoma and paraganglioma.